Pre-Clinical Toxicity Study and Safety Assessment of Candidate Live Pertussis Vaccine for Intranasal Administration
https://doi.org/10.31631/2073-3046-2018-17-98-108
Abstract
Against the backdrop of mass parenteral immunization by present pertussis vaccines the incidence rate of pertussis is recorded in many countries, as well as among adolescents and adults, according to the World Health Organisation data. The number of cases of pertussis complicated to detect is increased, meaning atypical forms and inapparent bacteria carrying. In the presence of appearance of Bordetella pertussis strains of «new» genotype the efficacy of current pertussis vaccines is decreased. Existing epidemiologic situation cries out for development of new, more efficient pertussis vaccines and improvement of immunization methods and schedules. The most promising for this problem solution are live pertussis vaccines, constructed with genetic engineering methods.
The goal of present research is studying of toxicity and safety of innovative recombinant live pertussis vaccine for intranasal administration in animals.
Obtained results demonstrate the absence of specific toxicity of candidate vaccine and its use safety in intranasal applying.
About the Authors
L. N. Sinyashina
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Russian Federation
Russian Federation
Lyudmila N. Sinyashina – Dr. Sci. (Med.), leading research associate.
Moscow.
E. G. Semin
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Russian Federation
Russian Federation
Evgenij G. Semin – junior research associate.
Moscow.
A. Yu. Medkova
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Russian Federation
Russian Federation
Alisa Yu. Medkova – Cand. Sci. (Med.), research associate.
Moscow.
R. A. Siundiukova
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Russian Federation
Russian Federation
Rezida A. Siundiukova – Cand. Sci. (Biol.), senior research associate.
Moscow.
G. I. Karataev
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Russian Federation
Russian Federation
Gennadij I. Karataev – Dr. Sci. (Biol.), leading researcher associate, head laboratory of genetics of bacteria.
Moscow.
References
1. Wolter N, Mupere E, Tan T, et al. Pertussis in Africa: Findings and recommendations of the Global Pertussis Initiative (GPI). Vaccine. 2018; 36, 18: 2385–2393. doi: 10.1016/j. vaccine.2018.03.025
2. Pimenova AS, Borisova OYu, Tsvircun OV, et al. Efficiency of application of molecular-genetic diagnostics in case of inspection of the schools of a whooping cough. Russian Journal of Infection and Immunity. 2017; 7 (2): 162–170. (In Russ.) doi: 10.15789/2220-7619-2017-2-162-170
3. The immunological basis for immunization series: module 4: pertussis (Immunological basis for immunization series; module 4). World Health Organization 2017. ISBN 978-92-4-151317-3. Available at: http://apps.who.int/iris/bitstream/handle/10665/259388/9789241513173-eng.pdf. Accessed: 1 Mar 2018.
4. Bobachenko IV. Pertussis in children. Saint-Petersburg: Kommentariy; 2014 (In Russ.)
5. Borisova OIu, Mazurova IK, Ivashinnikova GA, et al. Characteristics of Bordetelia pertussis strains isolated from pertussis patients in Moscow by using multilocus sequencing. Epidemiol. and Infection Diseases. Immunobiol. 2012; (2): 28–34. (In Russ.)
6. Mooi FR. Bordetella pertussis and vaccination: the persistence of a gene-tically monomorphic pathogen. Infect. Genet. Evol. 2010; 10 (1): 36–49.
7. Warfel JM, Merkel TJ, et al. Bordetella pertussis infection induces a mucosal IL-17 respons and long-live Th17 and Th1 immune cells in nonhuman primates. Mucosal Immuunol. 2013; 6 (4): 787–796.
8. Warfel, JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl., Acad. Sci. USA. 2014;111:787-792.
9. Karataev GI, Sinyashina LN, Medkova AY, et al. Insertional inactivation of virulence operon in population of persistent Bordetella pertussis bacteria. Russian journal of genetics. 2016; 52 (4):422–430. (In Russ.)
10. Kubrava DT, Medkova AY, Sinyashina LN, et al. Experimental whooping cough of nonhuman primate. Annals of the Russian academy of medical sciences. 2013; 68 (8): 28–33. (In Russ.)
11. Warfel JM, Zimmerman LI, Merkel TJ. Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis. Clin. Vaccine Immunol. 2015; 23 (1): 47–54. doi: 10.1128/CVI.00449-15
12. Locht C, Papin JF, Lecher S, et al. Live attenuated pertussis vaccine BPZE1 protects baboons against B. pertussis. Disease and infection. 2017;216:117.
13. Karataev GI, Sinyashina LN. Attenuirovanniye bacterii Bordetella pertussis vaktsina protiv vozbuditelya kokliusha. Patent RUS № 2455024 С1; 2012. (In Russ.)
14. Semin EG, Sinyashina LN, Medkova AYu, et al. Construction of recombinant attenuated Bordetella pertussis bacteria of ptxP3 genotype. J. of microbiol., epidemiol. and immunobiol. 2018; 4: 33–41. (In Russ).
15. Mironov AN. Manual on preclinical research of medicinal preparations (immunobiological medicinal preparations). Moscow: Grif i К; 2012. (In Russ.).
16. Alekseeva IА. Mikrobiologicheskiy nadzor za kachestvom kokliushnogo komponenta kombinirovannikh vaktsin [dissertation]. Moscow; 2015. (In Russ.)
Review
For citations:
Sinyashina L.N., Semin E.G., Medkova A.Yu., Siundiukova R.A., Karataev G.I. Pre-Clinical Toxicity Study and Safety Assessment of Candidate Live Pertussis Vaccine for Intranasal Administration. Epidemiology and Vaccinal Prevention. 2018;17(6):98-108. (In Russ.) https://doi.org/10.31631/2073-3046-2018-17-98-108
Views:
1453
Email this article 